Platinum resistance and biochemical recurrence of ovarian cancer
Conditions
Interventions
Case series:antiangiogenic drugs
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged between 20 and 75 years; 2. all patients underwent tumor cell ablation and were diagnosed as epithelial ovarian cancer by histopathology. 3. the patient has received at least first-line platinum-based chemotherapy with evidence of recurrence and has stopped using platinum-based drugs for less than 6 months, including refractory ovarian cancer with disease progression during the use of platinum-based chemotherapy; 4. good physical condition: Eastern Cooperative Oncology Group (ECOG) score =3 months; 6. there are measurable lesions; 7. volunteered to participate in this project, agreed to the treatment follow-up and reexamination of the center, and did not participate in other clinical researchers within 3 months.
Exclusion criteria
Exclusion criteria: 1) allergy to antiangiogenic targeted drugs; 2) patients with serious heart disease or history (angina pectoris, intractable hypertension, congestive heart failure, myocardial infarction, high risk uncontrolled arrhythmia, and heart valve disease); 3) inflammation, unhealed wounds, ulcers or bleeding diseases; 4) the second primary malignant tumor; 5) patients with uncontrollable neurological, mental illness or mental disorder, poor compliance and inability to cooperate and describe treatment responses; 6) patients who also participate in other clinical trials; 7) other circumstances in which the investigator considers the patient inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Countries
China
Contacts
Public ContactZhang Mei
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed